HCV infection should be managed in specialist centres.
نویسنده
چکیده
Chronic hepatitis C virus (HCV) infection may cause slowly progressive chronic hepatitis, cirrhosis, advanced liver failure, and hepatocellular carcinoma. These varying outcomes of type C hepatitis pose a challenge and responsibility which requires firstly, that antiviral treatment is targeted as precisely as possible to those who have progressive disease, and secondly, that patients with advanced disease are managed by specialist centres with the capability of minimising the morbidity of the disease. Presently, most patients with community and hospital associated hepatitis C requiring treatment are referred to specialist liver centres. The hepatologist has a pivotal role in the management of chronic hepatitis C. This includes the differential diagnosis, clinical management, and assessment of the stage of disease. Hepatology has become an increasingly specialised discipline and hepatologists are ideally placed to collate investigations and to ensure the appropriate management of coexisting liver disease. Specialist hepatologists also provide the continuity and follow up required for understanding the sometimes complex dynamic nature of the disease. There is a unique requirement for the histopathological investigation of hepatitis C to inform and deliver the National Institute of Clinical Excellence (NICE) guidelines. Useful classifications for staging and grading of disease have been devised. There is a need for experienced clinical input to complement the interpretation of liver biopsies by histopathologists who should see sufficient numbers of patients with a full spectrum of disease. Liver biopsy moreover is an invasive technique and requires skilled and practised operators. If haemostasis is abnormal, transjugular biopsies may be required. The hepatologist is required to ascertain the trajectory of the disease in chronically infected patients to make informed decisions regarding treatment. Alpha interferon and ribavirin are the current standard of care. NICE makes clear recommendations for the treatment of chronic disease, and the appropriate application of this treatment is an obvious example of specialist input to ensure that national guidelines are followed (wws.nice.org.uk). The optimal timing of treatment necessary to minimise unnecessary treatment for those who would not progress to severe chronic disease, but avoiding treatment failure through delay, is being established. Generally, hepatologists are engaged in applying antiviral therapy for this disease and in monitoring patients for response or complications during treatment. They are also well placed to assess indications and contraindications for antiviral therapy and the management of resistance, relapse, or non-response. Hepatologists take a specialist research and clinical interest in therapeutic trials for HCV infection and are at the forefront of emerging technologies. 5 There is clearly a mandatory role for the hepatologist in the management of cirrhosis. This applies to the management of complications including the medical, endoscopic and portosystemic intrahepatic shunt management of variceal bleeding, and other complications of portal hypertension, including ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, and the renal dysfunction associated with cirrhosis. Specialist transplant hepatologists together with pathologists, radiologists, and the surgeon provide the tools and full range of expertise for the seamless management of patients with decompensated cirrhosis. Appropriately timed referral for transplantation demands particular training and experience. To date, hepatologists have played a pivotal role in the diagnosis and management of hepatocellular carcinoma (HCC). This includes aspects of surveillance for small HCC as well as the imaging and diagnosis of focal lesions. Hepatologists and interventional radiologists must be involved in decisions regarding the treatment of HCC, including liver biopsy, surgical resection, liver transplantation, or targeted treatment, which in some cases may be curative. The management of advanced HCC is aided by chemotherapy and specialist oncologists. The hepatologist has also begun to play a unique role in coinfection clinics, assessing the clinical management of coinfection with human immunodeficiency virus (HIV) and HCV (or hepatitis B). Together with the retrovirologist, decisions must now be made regarding the prescription of complex multiple antiretroviral agents and their combination with other antiviral agents in this rapidly evolving field. Liver involvement in acquired immunodeficiency syndrome (AIDS) or antiretroviral therapy also requires the involvement of a hepatologist. A number of extrahepatic manifestations, including renal disease, mixed essential cryoglobulinaemia, and lymphoma are being encountered in association with hepatitis C, which may require assessment by the hepatologist and clinical interactions with appropriate specialists. Hepatologists have overseen the generation of guidelines for the management of hepatitis C, including the NIH and EASL guidelines. Generally, the specialist with liver disease is likely to act as the “driver” in developing recommendations for implementing the requisite virological and other laboratory investigations, and for steering the migration of tests from the research laboratory to clinical practice. In this way a composite of clinical and laboratory results enable the development of suitable diagnostic algorithms. In turn, G Dusheiko Royal Free and University College School of Medicine, London NW3 2QG, UK; [email protected]
منابع مشابه
Infection control of hepatitis C in Dutch dialysis centres.
BACKGROUND In dialysis patients, blood transfusions and long-term dialysis are well-known risk factors for transmission of hepatitis C virus (HCV). Transmission of HCV by transfusions has become extremely rare since the introduction of antibody screening. However, nosocomial transmission of HCV within dialysis units still occurs. We performed a survey of current infection control measures again...
متن کاملAustralian recommendations for the management of hepatitis C virus infection: a consensus statement.
Chronic hepatitis C virus (HCV) infection affects 230 000 Australians, who are at risk of progressive liver fibrosis leading to cirrhosis, liver failure and hepatocellular carcinoma. HCV infection is curable, and all Australians living with HCV should be considered for antiviral therapy. Interferon-free regimens involving combinations of sofosbuvir, ledipasvir, daclatasvir and/or ribavirin for ...
متن کاملPublic health clinic-based hepatitis C testing and linkage to care in Baltimore.
Testing and linkage to care are important determinants of hepatitis C virus (HCV) treatment effectiveness. Public health clinics serve populations at high risk of HCV. We investigated their potential to serve as sites for HCV testing, initiation of and linkage to HCV care. Cross-sectional study of patients accessing sexually transmitted infection (STI) care at the Baltimore City Health Departme...
متن کاملHepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors
BACKGROUND Patients receiving maintenance haemodialysis (HD) are at higher risk for acquiring Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections than the general population. Strict infection control measures are essential to prevent nosocomial transmission. We aimed to investigate the incidence and prevalence of HBV and HCV infection in the HD population of Libya as well as risk fac...
متن کاملMultidisciplinary managed care networks-Life-saving interventions for hepatitis C patients.
Successful hepatitis C virus (HCV) therapy depends on effective pathways of care. Over two decades, we have developed four sequential models of care latterly using a multidisciplinary managed care network to improve HCV testing, care and treatment. This was a cohort study to evaluate the effectiveness of care pathways, carried out using all HCV antibody-positive individuals tested in a geograph...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Gut
دوره 51 5 شماره
صفحات -
تاریخ انتشار 2002